Toll like receptor 2, 4, and 9 signaling promotes autoregulative tumor cell growth and VEGF/PDGF expression in human pancreatic cancer

International Journal of Molecular Sciences

Volumn 17, Issue 12, 2016, Pages

  Grimmig, Tanja ^a   Moench, Romana ^a   Kreckel, Jennifer ^a   Haack, Stephanie ^a   Rueckert, Felix ^b   Rehder, Roberta ^c   Tripathi, Sudipta ^d   Ribas, Carmen ^c   Chandraker, Anil ^d   Germer, Christoph T ^a   Gasser, Martin ^a   Waaga Gasser, Ana Maria ^a,d  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Evangelical College of Parana   (Brazil)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Inflammation; Pancreatic cancer; TLR2; TLR4; TLR9; Tumor growth

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN BCL XL; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; VASCULOTROPIN; ADENOSINE TRIPHOSPHATE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL X; PROTEIN KINASE B; TARGET OF RAPAMYCIN KINASE; TOLL LIKE RECEPTOR; VASCULOTROPIN A;

ARTICLE; CANCER STAGING; CELL PROLIFERATION ASSAY; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; INTRACELLULAR SIGNALING; PANCREAS CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RNA EXTRACTION; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR GROWTH; WESTERN BLOTTING; APOPTOSIS; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PANCREAS TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MAP KINASE SIGNALING SYSTEM; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PHOSPHATIDYLINOSITOL 3-KINASES; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9; TOLL-LIKE RECEPTORS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85005949827     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17122060     Document Type: Article

References (46)

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 2015, 65, 5-29.
2. Malka, D.; Hammel, P.; Maire, F.; Rufat, P.; Madeira, I.; Pessione, F.; Levy, P.; Ruszniewski, P. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002, 51, 849-852.
3. Whitcomb, D.C. Inflammation and cancer V. Chronic pancreatitis and pancreatic cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287, G315-G319.
4. Farrow, B.; Evers, B.M. Inflammation and the development of pancreatic cancer. Surg. Oncol. 2002, 10, 153-169.
5. Janeway, C.A., Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 1989, 54, 1-13.
6. Rubartelli, A.; Lotze, M.T. Inside, outside, upside down: Damage-associated molecular-pattern molecules (damps) and redox. Trends Immunol. 2007, 28, 429-436.
7. Grimm, M.; Kim, M.; Rosenwald, A.; Heemann, U.; Germer, C.T.; Waaga-Gasser, A.M.; Gasser, M. Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in colorectal cancer points to a specific role for inflammation-induced tlrs in tumourigenesis and tumour progression. Eur. J. Cancer 2010, 46, 2849-2857.
8. Grimmig, T.; Matthes, N.; Hoeland, K.; Tripathi, S.; Chandraker, A.; Grimm, M.; Moench, R.; Moll, E.M.; Friess, H.; Tsaur, I. et al. TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer. Int. J. Oncol. 2015, 47, 857-866.
9. Mai, C.W.; Kang, Y.B.; Pichika, M.R. Should a toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: Its expression and effects in the ten most common cancers. Onco Targets Ther. 2013, 6, 1573-1587.
10. Muccioli, M.; Benencia, F. Toll-like receptors in ovarian cancer as targets for immunotherapies. Front. Immunol. 2014, 5, 341.
11. Dajon, M.; Iribarren, K.; Cremer, I. Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword. Immunobiology 2016.
12. Gonzalez-Reyes, S.; Marin, L.; Gonzalez, L.; Gonzalez, L.O.; del Casar, J.M.; Lamelas, M.L.; Gonzalez-Quintana, J.M.; Vizoso, F.J. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 2010, 10.
13. Ridnour, L.A.; Cheng, R.Y.; Switzer, C.H.; Heinecke, J.L.; Ambs, S.; Glynn, S.; Young, H.A.; Trinchieri, G.; Wink, D.A. Molecular pathways: Toll-like receptors in the tumor microenvironment—Poor prognosis or new therapeutic opportunity. Clin. Cancer Res. 2013, 19, 1340-1346.
14. Sheyhidin, I.; Nabi, G.; Hasim, A.; Zhang, R.P.; Ainiwaer, J.; Ma, H.; Wang, H. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J. Gastroenterol. 2011, 17, 3745-3751.
15. Park, H.D.; Lee, Y.; Oh, Y.K.; Jung, J.G.; Park, Y.W.; Myung, K.; Kim, K.H.; Koh, S.S.; Lim, D.S. Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation. Oncogene 2011, 30, 201-211.
16. Vaz, J.; Andersson, R. Intervention on toll-like receptors in pancreatic cancer. World J. Gastroenterol. 2014, 20, 5808-5817.
17. Eigenbrod, T.; Dalpke, A.H. TLR7 inhibition: A novel strategy for pancreatic cancer treatment? Jak-Stat 2013, 2, e23011.
18. Cherfils-Vicini, J.; Platonova, S.; Gillard, M.; Laurans, L.; Validire, P.; Caliandro, R.; Magdeleinat, P.; Mami-Chouaib, F.; Dieu-Nosjean, M.C.; Fridman, W.H. et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J. Clin. Investig. 2010, 120, 1285-1297.
19. Chiron, D.; Pellat-Deceunynck, C.; Amiot, M.; Bataille, R.; Jego, G. TLR3 ligand induces NF-κB activation and various fates of multiple myeloma cells depending on IFN-α production. J. Immunol. 2009, 182, 4471-4478.
20. Hsu, R.Y.; Chan, C.H.; Spicer, J.D.; Rousseau, M.C.; Giannias, B.; Rousseau, S.; Ferri, L.E. LPS-induced TLR4 signaling in human colorectal cancer cells increases β1 integrin-mediated cell adhesion and liver metastasis. Cancer Res. 2011, 71, 1989-1998.
21. Thuringer, D.; Hammann, A.; Benikhlef, N.; Fourmaux, E.; Bouchot, A.; Wettstein, G.; Solary, E.; Garrido, C. Transactivation of the epidermal growth factor receptor by heat shock protein 90 via toll-like receptor 4 contributes to the migration of glioblastoma cells. J. Biol. Chem. 2011, 286, 3418-3428.
22. Takahashi, Y.; Kitadai, Y.; Bucana, C.D.; Cleary, K.R.; Ellis, L.M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995, 55, 3964-3968.
23. Ferrara, N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev. 2004, 25, 581-611.
24. Ho, Q.T.; Kuo, C.J. Vascular endothelial growth factor: Biology and therapeutic applications. Int. J. Biochem. Cell Biol. 2007, 39, 1349-1357.
25. Tsan, M.F.; Gao, B. Endogenous ligands of Toll-like receptors. J. Leukoc. Biol. 2004, 76, 514-519.
26. Liu, J.; Zhang, B.L.; Sun, C.L.; Wang, J.; Li, S.; Wang, J.F. High mobility group box1 protein is involved in acute inflammation induced by clostridium difficile toxin A. Acta Biochim. Biophys. Sin. 2016, 48, 554-562.
27. Shibuya, M. Vascular endothelial growth factor and its receptor system: Physiological functions in angiogenesis and pathological roles in various diseases. J. Biochem. 2013, 153, 13-19.
28. Shibuya, M.; Claesson-Welsh, L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell. Res. 2006, 312, 549-560.
29. Stuttfeld, E.; Ballmer-Hofer, K. Structure and function of VEGF receptors. IUBMB Life 2009, 61, 915-922.
30. Senger, D.R.; Galli, S.J.; Dvorak, A.M.; Perruzzi, C.A.; Harvey, V.S.; Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219, 983-985.
31. Heldin, C.H. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun. Signal. 2013, 11.
32. Moench, R.; Grimmig, T.; Kannen, V.; Tripathi, S.; Faber, M.; Moll, E.-M.; Chandraker, A.; Lissner, R.; Germer, C.-T.; Waaga-Gasser, A.M. et al. Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer. Oncotarget 2016, 5.
33. Taeger, J.; Moser, C.; Hellerbrand, C.; Mycielska, M.E.; Glockzin, G.; Schlitt, H.J.; Geissler, E.K.; Stoeltzing, O.; Lang, S.A. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol. Cancer Ther. 2011, 10, 2157-2167.
34. Von Marschall, Z.; Cramer, T.; Hocker, M.; Burde, R.; Plath, T.; Schirner, M.; Heidenreich, R.; Breier, G.; Riecken, E.O.; Wiedenmann, B. et al. De novo expression of vascular endothelial growth factor in human pancreatic cancer: Evidence for an autocrine mitogenic loop. Gastroenterology 2000, 119, 1358-1372.
35. Weissmueller, S.; Manchado, E.; Saborowski, M.; Morris, J.P.t.; Wagenblast, E.; Davis, C.A.; Moon, S.H.; Pfister, N.T.; Tschaharganeh, D.F.; Kitzing, T. et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell 2014, 157, 382-394.
36. Nandy, D.; Mukhopadhyay, D. Growth factor mediated signaling in pancreatic pathogenesis. Cancers 2011, 3, 841-871.
37. Meteoglu, I.; Erdogdu, I.H.; Meydan, N.; Erkus, M.; Barutca, S. NF-κB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues. J. Exp. Clin. Cancer Res. 2008, 27.
38. Zhang, Z.; Zheng, Y.; Zhu, R.; Zhu, Y.; Yao, W.; Liu, W.; Gao, X. The ERK/eIF4F/Bcl-XL pathway mediates SGP-2 induced osteosarcoma cells apoptosis in vitro and in vivo. Cancer Lett. 2014, 352, 203-213.
39. Shcheblyakov, D.V.; Logunov, D.Y.; Tukhvatulin, A.I.; Shmarov, M.M.; Naroditsky, B.S.; Gintsburg, A.L. Toll-Like Receptors (TLRs): The Role in Tumor Progression. Acta Naturae 2010, 2, 21-29.
40. Street, S.E.; Cretney, E.; Smyth, M.J. Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis. Blood 2001, 97, 192-197.
41. Swann, J.B.; Hayakawa, Y.; Zerafa, N.; Sheehan, K.C.; Scott, B.; Schreiber, R.D.; Hertzog, P.; Smyth, M.J. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J. Immunol. 2007, 178, 7540-7549.
42. Stockfleth, E.; Trefzer, U.; Garcia-Bartels, C.; Wegner, T.; Schmook, T.; Sterry, W. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: An overview. Br. J. Dermatol. 2003, 149, 53-56.
43. Krieg, A.M. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008, 27, 161-167.
44. Kanzler, H.; Barrat, F.J.; Hessel, E.M.; Coffman, R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 2007, 13, 552-559.
45. Balkwill, F.; Coussens, L.M. Cancer: An inflammatory link. Nature 2004, 431, 405-406.
46. Rakoff-Nahoum, S.; Medzhitov, R. Role of toll-like receptors in tissue repair and tumorigenesis. Biochemistry 2008, 73, 555-561.